David B. Donner, PhD

Education

Queens College, New York, NY, B.A., 1966, Chemistry
Rensselaer Polytechnic Institute, New York, NY, Ph.D., 1972, Chemistry
Cornell University, Ithaca, NY, post-doc, 1972-1973, Biochemistry

Honors & Awards

• 7/82 to 6/87
  NIH Career Development Award
• 1/82 to 6/82
  American Cancer Society Faculty Research Award
• 1984
  Louise & Alston Boyer Young Investigator Award for Laboratory Research
• 1978-79
  American Diabetes Association Research and Development Award
• 1962-1966
  NY State Regents Scholarship
• 1962-1966
  NY State Scholar Incentive Award

Selected Publications

1. Ricardo J. Antonia, Kan Toriguchi, Eveliina Karelehto, Dania Annuar, Luika Timmerman, Noura Tbeileh, Aras N. Mattis, Carlos U. Corvera, Kenzo Hirose, Eric K. Nakakura, David B. Donner, Robert S. Warren. Patient-derived organoids for personalized drug screening in intrahepatic cholangiocarcinoma. Journal of Clinical Oncology. 2020 Feb 1; 38(4_suppl):581-581.  View on PubMed
2. Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma. PLoS One. 2019; 14(7):e0219469.  View on PubMed
3. Donner DB, Ruan DT, Toriguchi K, Bergsland EK, Nakakura EK, Lin MH, Antonia RJ, Warren RS. Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases. Transl Oncol. 2019 Mar; 12(3):550-560.  View on PubMed
4. Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. . 2018 12; 17(12):2702-2709.  View on PubMed
5. K. Toriguchi, M. Lin, E. Nakakura, C. Corvera, B. Hann, D. Donner, R. Warren. An approach to patient-specific treatment of intrahepatic cholangiocarcinoma (ICC): drug screens with patient-derived spheroids identify mTOR as a viable and druggable target. Hepato Pancreato Biliary. 2018 Sep 1; 20:s690-s691.  View on PubMed
6. Tartaglione G, Stoeckli SJ, de Bree R, Schilling C, Flach GB, Bakholdt V, Sorensen JA, Bilde A, von Buchwald C, Lawson G, Dequanter D, Villarreal PM, Forcelledo MF, Amezaga JA, Moreira A, Poli T, Grandi C, Vigili MG, O'Doherty M, Donner D, Bloemena E, Rahimi S, Gurney B, Haerle SK, Broglie MA, Huber GF, Krogdah AL, Sebbesen LR, Odell E, Junquera Gutierrez LM, Barbier L, Santamaria-Zuazua J, Jacome M, Nollevaux MC, Bragantini E, Lothaire P, Silini EM, Sesenna E, Dolivet G, Mastronicola R, Leroux A, Sassoon I, Sloan P, Colletti PM, Rubello D, McGurk M. Sentinel Node in Oral Cancer: The Nuclear Medicine Aspects. A Survey from the Sentinel European Node Trial. Clin Nucl Med. 2016 Jul; 41(7):534-42.  View on PubMed
7. Maines F, Caffo O, Donner D, Sperduti I, Bria E, Veccia A, Chierichetti F, Tortora G, Galligioni E. Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers. Future Oncol. 2016 Feb; 12(3):333-42.  View on PubMed
8. Schilling C, Stoeckli SJ, Haerle SK, Broglie MA, Huber GF, Sorensen JA, Bakholdt V, Krogdahl A, von Buchwald C, Bilde A, Sebbesen LR, Odell E, Gurney B, O'Doherty M, de Bree R, Bloemena E, Flach GB, Villarreal PM, Fresno Forcelledo MF, Junquera Gutiérrez LM, Amézaga JA, Barbier L, Santamaría-Zuazua J, Moreira A, Jacome M, Vigili MG, Rahimi S, Tartaglione G, Lawson G, Nollevaux MC, Grandi C, Donner D, Bragantini E, Dequanter D, Lothaire P, Poli T, Silini EM, Sesenna E, Dolivet G, Mastronicola R, Leroux A, Sassoon I, Sloan P, McGurk M. Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer. Eur J Cancer. 2015 Dec; 51(18):2777-84.  View on PubMed
9. Depeille P, Henricks LM, van de Ven RA, Lemmens E, Wang CY, Matli M, Werb Z, Haigis KM, Donner D, Warren R, Roose JP. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth. Nat Cell Biol. 2015 Jun; 17(6):804-15.  View on PubMed
10. Farkas C, Martins CP, Escobar D, Hepp MI, Castro AF, Evan G, Gutiérrez JL, Warren R, Donner DB, Pincheira R. Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress. PLoS One. 2013; 8(9):e73817.  View on PubMed
11. Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013 Oct 15; 19(20):5777-87.  View on PubMed
12. Schiavi F, Demattè S, Cecchini ME, Taschin E, Bobisse S, Del Piano A, Donner D, Barbareschi M, Manera V, Zovato S, Erlic Z, Savvoukidis T, Barollo S, Grego F, Trabalzini F, Amistà P, Grandi C, Branz F, Marroni F, Neumann HP, Opocher G. The endemic paraganglioma syndrome type 1: origin, spread, and clinical expression. J Clin Endocrinol Metab. 2012 Apr; 97(4):E637-41.  View on PubMed
13. Gregory S. Ducker, Chloe Evelyn Atreya, Jeffrey Simko, Eric K. Nakakura, Emily K. Bergsland, David B. Donner, Kevan M. Shokat, Robert S. Warren. Effect of PIK3CA and KRAS mutations on sensitivity to ATP-competitive mTOR inhibitors in a primary xenograft model of colorectal carcinoma. Journal of Clinical Oncology. 2012 Feb 1; 30(4_suppl):483-483.  View on PubMed
14. Lin CI, Barletta JA, Nehs MA, Morris ZS, Donner DB, Whang EE, Jeong JW, Kimura S, Moore FD, Ruan DT. Thyroid-specific knockout of the tumor suppressor mitogen-inducible gene 6 activates epidermal growth factor receptor signaling pathways and suppresses nuclear factor-?B activity. Surgery. 2011 Dec; 150(6):1295-302.  View on PubMed
15. Mitra R, Guo Z, Milani M, Mesaros C, Rodriguez M, Nguyen J, Luo X, Clarke D, Lamba J, Schuetz E, Donner DB, Puli N, Falck JR, Capdevila J, Gupta K, Blair IA, Potter DA. CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET). J Biol Chem. 2011 May 20; 286(20):17543-59.  View on PubMed
16. Y. Wang, D. Donner, A. Venook, E. Bergsland, R. Warren, E. Nakakura. A Primary Xenograft Model of Pancreatic Neuroendocrine Carcinoma Maintains a Neuroendocrine Tumor Gene Expression Signature. Journal of Surgical Research. 2011 Feb 1; 165(2):296.  View on PubMed
17. Chi-Iou Lin, Jinyan Du, Wen Shen, Edward E. Whang, David B. Donner, Nick Griff, Frank He, Francis D. Moore, Orlo H. Clark, Daniel T. Ruan. Mitogen-Inducible Gene-6 Is a Multifunctional Adaptor Protein with Tumor Suppressor-Like Activity in Papillary Thyroid Cancer. Endocrine Reviews. 2011 Feb 1; 32(1):157-158.  View on PubMed
18. Chi-Iou Lin, Jinyan Du, Wen Shen, Edward E. Whang, David B. Donner, Nick Griff, Frank He, Francis D. Moore, Orlo H. Clark, Daniel T. Ruan. Mitogen-Inducible Gene-6 Is a Multifunctional Adaptor Protein with Tumor Suppressor-Like Activity in Papillary Thyroid Cancer. Endocrinology. 2011 Feb 1; 25(2):373-373.  View on PubMed
19. Lin CI, Du J, Shen WT, Whang EE, Donner DB, Griff N, He F, Moore FD, Clark OH, Ruan DT. Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer. J Clin Endocrinol Metab. 2011 Mar; 96(3):E554-65.  View on PubMed
20. Lin CI, Whang EE, Donner DB, Du J, Lorch J, He F, Jiang X, Price BD, Moore FD, Ruan DT. Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. Mol Cancer Res. 2010 Sep; 8(9):1217-26.  View on PubMed

Go to UCSF Profiles, powered by CTSI